Regeneron Pharmaceuticals (REGN) stock
Last close $920.69 on 2026-11-20 (-0.29%) · Sector: Healthcare
Regeneron Pharmaceuticals is an American biotechnology company founded in 1988 and headquartered in Westchester County, New York. It develops medicines for serious diseases and earns most of its money by selling prescription drugs, along with income from partnerships with other drugmakers.
Regeneron's business is growing: revenue rose 18.6% and the latest quarter was its strongest in this data, with net income of $1.95 billion. Over the past year the stock returned 20.9% versus 3.2% for the S&P 500, a broad market index, so it beat the market. The stock trades 7.2% below its 52-week high and is 11.0% above its 50-day average. Insiders sold $59.1 million of stock over the last 90 days and made no purchases, and the stock has moved sharply after some earnings reports.
Key numbers
- Market cap: $97.2B
- Revenue (last 12 months): $16.90B
- Revenue growth: +18.6%
- Operating margin: 28.8%
- P/E: 20.4
- P/S: 5.8
- Debt to equity: 0.06
- Current ratio: 3.35
Quality score
Overall 64/100 · growth 45 · profitability 55 · financial health 84 · value 72
Performance and risk
1-year return +20.9% vs S&P 500 +3.1% · volatility 33.6% (S&P 500 14.2%) · largest drop -26.1% · beta 0.42
Stock move the day after earnings
- 2026-01-12: -3.6%
- 2026-01-30: -1.1%
- 2026-04-08: +2.0%
- 2026-04-29: -6.2%
- 2026-07-06: -0.7%
- 2026-07-30: +6.2%
- 2026-10-06: +1.7%
- 2026-10-30: +13.3%
Insider trades (12 months)
Bought $0.0M · sold $65.0M
REGN stock research · REGN options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.